CUV · ASX

Clinuvel Pharmaceuticals Limited (ASX:CUV)

AU$11.84

 0.6 (5.338%)
ASX:Live
17/09/2025 04:10:28 PM
Short Sold <-1 over the month HALO Small HALO Ords HALO Dividend Growth HALO Consensus Value +6
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CUV Overview

CUV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Strong

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Very Weak

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Neutral

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Strong

Balance Sheet

Very Strong

About CUV

Website

Clinuvel Pharmaceuticals Limited

Telephone

61.3.9660.4900

Address

Level 11 535 Bourke Street Melbourne, Victoria (VIC) 3000

Description

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

CUV Price Chart

Key Stats

Market Cap

AU$593.46M

PE

17.30

EV/EBITDA

9.5

Dividends Overview

DIV Yield

.4%

Franking

100%

Ex Dividend Date (est.)

04-Sep-25

Market Data

52 weeks range

Low 9.41 - 15.2

Trade Value (12mth)

AU$367,460.00

1 week

11.7%

1 month

-3.82%

YTD

-1.25%

1 year

-20.96%

All time high

45.88

Key Fundamentals

EPS 3 yr Growth

70.90%

EBITDA Margin

44.70%

Operating Cashflow

$41m

Free Cash Flow Return

18.50%

ROIC

16.30%

Interest Coverage

1,072.70

Quick Ratio

9.30

Other Data

Shares on Issue (Fully Dilluted)

50m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-26

Ex Dividend Date (est.)

04-Sep-25

Next Dividend Pay Date (est.)

19-Sep-25

Reporting Currency

AUD

Short Sell (% of issue)

4.30

CUV Announcements

Latest Announcements

Date Announcements

17 September 25

Becoming a substantial holder

×

Becoming a substantial holder

15 September 25

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

05 September 25

Chair's Letter to Shareholders

×

Chair's Letter to Shareholders

03 September 25

Date of Annual General Meeting

×

Date of Annual General Meeting

29 August 25

CLINUVEL Annual Results - Investor Webinar

×

CLINUVEL Annual Results - Investor Webinar

28 August 25

Appendix 4E and Annual Report to Shareholders 2025

×

Appendix 4E and Annual Report to Shareholders 2025

28 August 25

CLINUVEL delivers ninth consecutive revenues growth & profit

×

CLINUVEL delivers ninth consecutive revenues growth & profit

28 August 25

Dividend/Distribution - CUV

×

Dividend/Distribution - CUV

28 August 25

Appendix 4G

×

Appendix 4G

28 August 25

Corporate Governance Statement

×

Corporate Governance Statement

28 August 25

Investor Presentation

×

Investor Presentation

22 August 25

CLINUVEL preparing upgrade of ADR program, NASDAQ uplist

×

CLINUVEL preparing upgrade of ADR program, NASDAQ uplist

21 August 25

CLINUVEL Annual Results - Investor Webinar

×

CLINUVEL Annual Results - Investor Webinar

07 August 25

Bioshares Biotech Summit presentation

×

Bioshares Biotech Summit presentation

30 July 25

Presentation to BTIG Biotech Conference

×

Presentation to BTIG Biotech Conference

02 July 25

Notification of cessation of securities - CUV

×

Notification of cessation of securities - CUV

24 June 25

German Non-deal Roadshow Presentation

×

German Non-deal Roadshow Presentation

19 June 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

18 June 25

Becoming a substantial holder

×

Becoming a substantial holder

18 June 25

Study confirms NB-UVB needed to activate repigmentation

×

Study confirms NB-UVB needed to activate repigmentation

13 June 25

SCENESSE successfully administered to paediatric EPP patient

×

SCENESSE successfully administered to paediatric EPP patient

13 June 25

CLINUVEL management update

×

CLINUVEL management update

04 June 25

SCENESSE in Vitiligo - A Global Update

×

SCENESSE in Vitiligo - A Global Update

22 May 25

SCENESSE EPP data featured at EADV Symposium

×

SCENESSE EPP data featured at EADV Symposium

09 May 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

07 May 25

CUV recruits 200 patients in Phase III vitiligo trial CUV105

×

CUV recruits 200 patients in Phase III vitiligo trial CUV105

CUV Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.62 0.72 0.72 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.59 0.70 0.72 Lock Lock Lock
     Growth % Lock Lock Lock Lock 46.6 15.5 1.0 Lock Lock Lock
     PE X Lock Lock Lock Lock 34.6 21.1 17.3 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 21.7 11.8 9.5 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.81 0.87 0.78 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.65 0.57 0.76 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.1 6.9 -10.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock 3.7 3.7 7.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.05 0.05 0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 25.0 0.0 0.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.3 0.5 0.4 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 8 7 7 Lock Lock Lock
BPS $ Lock Lock Lock Lock 3.33 4.05 4.80 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 3.33 4.05 4.80 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.2 21.7 18.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 52 51 50 Lock Lock Lock
Basic m Lock Lock Lock Lock 49 50 50 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 78 88 95 Lock Lock Lock
     Growth % Lock Lock Lock Lock 19.2 12.6 7.8 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 14 21 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 51 58 63 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.5 14.5 7.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 64.6 65.7 65.8 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 35 34 34 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 42 45 42 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.2 7.3 -5.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 53.2 50.7 44.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 41 44 41 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.7 6.6 -5.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock 52.2 49.4 43.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 46 51 52 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 15 15 15 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 31 36 36 Lock Lock Lock
     Growth % Lock Lock Lock Lock 46.6 16.4 1.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 39.1 40.4 38.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 37 37 41 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 6 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -29 -48 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -2 -4 -3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 36 31 41 Lock Lock Lock
     Growth % Lock Lock Lock Lock -9.0 -12.3 29.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.5 0.4 0.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 157 184 224 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 195 232 273 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -156 -183 -224 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 30 29 32 Lock Lock Lock
Equity $m Lock Lock Lock Lock 165 203 241 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 165 204 241 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.7 23.1 18.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 15.7 15.4 13.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 18.6 17.6 15.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 28.0 23.6 18.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 21.0 19.3 16.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 25.3 20.1 18.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock N/A 1,076.4 1,072.7 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -3.7 -4.1 -5.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -94.6 -90.1 -92.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 7.4 8.8 9.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 7.1 8.4 9.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 82.7 82.8 85.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 144.8 147.0 151.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.1 3.6 3.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 4.9 3.0 3.3 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.5 0.4 0.4 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 3.6 2.7 2.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.4 0.3 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.4 0.3 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 58.2 57.5 54.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 23.4 21.8 18.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 32.9 29.7 29.8 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 15.7 15.4 13.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 18.6 17.6 15.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 91.9 93.0 93.1 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 17.1 16.3 14.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 74.7 121.5 109.2 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 89.5 100.3 103.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 164.2 221.8 212.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 15.7 29.9 29.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 148.5 191.9 183.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

04-Sep-25

DIV Yield

.4%

Franking Level

100%

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.45%

Value ($M)

34

Prior Change

N/A

7 Day Change

0.10%

1 Month Change

-4.40%

3 Month Change

0.50%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CUV Shortsell

Frequently Asked Questions

The current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$11.84.
The 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$15.20.
The 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)? is AU$9.41.
The current TTM dividend payout for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 0.40.
The last dividend payment of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$0.05.
Clinuvel Pharmaceuticals Limited (CUV:ASX) has a franking level of 100.0%.
Clinuvel Pharmaceuticals Limited (CUV:ASX) is classified in the Healthcare.
The current P/E ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 17.30.
The current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$11.84.
The 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$15.20.
The 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)? is AU$9.41.
The current TTM dividend payout for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 0.40.
The last dividend payment of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$0.05.
Clinuvel Pharmaceuticals Limited (CUV:ASX) has a franking level of 100.0%.
Clinuvel Pharmaceuticals Limited (CUV:ASX) is classified in the Healthcare.
The current P/E ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 17.30.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.